Taiwan Set To Approve Human Trials Of Locally Made Bird Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
Taiwanese health authorities expect the nation's emergency H5N1 vaccine to undergo its first human clinical trial by the end of this year. The vaccine was developed by the National Health Research Institute to use only in case of an emergency outbreak of the bird flu virus. The Department of Health is expected to authorize the trials by July 1. The restriction to emergencies only results from the institute's limited capacity to produce the vaccine, but DoH is seeking a partner in the private sector to enable greater production. (Click here for more